Publication at Third Faculty of Medicine |
2015
Abstract
Rheumatoid arthritis is a joints affecting illness with a potential to substantially negatively affect the movement and quality of life of patients. In the treatment, among others, a humanized monoclonal antibody against the IL-6 receptor, tocilizumab, is currently employed.
This substance is newly available in prefilled syringes for easy subcutaneous administration, hence a good compliance of patients is being expected. The text of this article covers so far experiences with this new form of drug across published clinical trials.